Immunotherapy can modify the spatial characteristics of CD8+ TRM cells via regulating their crosstalk with other immune cells, and the spatial distribution of CD8+ TRM cells in the HCC tumor microenvironment (TME) correlates with immune checkpoint blockade (ICB) therapeutic efficacy. This evidence concerns the gene CD8A and neoplasm.